Citation Impact
Citing Papers
A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein
2007 StandoutNobel
Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists
2010 StandoutScience
Cell entry mechanisms of SARS-CoV-2
2020 Standout
Selective Formation of Covalent Protein Heterodimers with an Unnatural Amino Acid
2011
De novo design of immunoglobulin-like domains
2022 StandoutNobel
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
Identification of an amino acid residue important for binding of methiothepin and sumatriptan to the human 5-HT1B receptor
1999
Ligand-selective receptor conformations revisited: the promise and the problem
2003
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development
2015
Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids
2015
A view on drug resistance in cancer
2019 StandoutNature
The pharmacology of headache
2000
Analysis of antibody-drug conjugates by comprehensive on-line two-dimensional hydrophobic interaction chromatography x reversed phase liquid chromatography hyphenated to high resolution mass spectrometry. I − Optimization of separation conditions
2016
Multiple Switches in G Protein-Coupled Receptor Activation
2009
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
A new anti-human Fc method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in serum from pre-clinical species
2016
Advances in PEGylation of important biotech molecules: delivery aspects
2008
Agonist-induced Phosphorylation of the Angiotensin II (AT1A) Receptor Requires Generation of a Conformation That Is Distinct from the Inositol Phosphate-signaling State
2000
Crystal structure of the human β2 adrenergic G-protein-coupled receptor
2007 StandoutNatureNobel
Lessons from constitutively active mutants of G protein-coupled receptors
2002
Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates
2015
Cutting-edge capillary electrophoresis characterization of monoclonal antibodies and related products
2016
Probing the β2 Adrenoceptor Binding Site with Catechol Reveals Differences in Binding and Activation by Agonists and Partial Agonists
2005 StandoutNobel
Opioid receptor random mutagenesis reveals a mechanism for G protein–coupled receptor activation
2003
Beyond natural antibodies: the power of in vitro display technologies
2011
Bioluminescence Resonance Energy Transfer Reveals Ligand-induced Conformational Changes in CXCR4 Homo- and Heterodimers
2005
Identification of an Allosteric Binding Site for Zn2+on the β2 Adrenergic Receptor
2002 StandoutNobel
Helix movement is coupled to displacement of the second extracellular loop in rhodopsin activation
2009
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
2004 Standout
Structure and function of an irreversible agonist-β2 adrenoceptor complex
2011 StandoutNatureNobel
Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor
2010 StandoutNatureNobel
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
Antibody therapy of cancer
2012 Standout
Insights from native mass spectrometry and ion mobility-mass spectrometry for antibody and antibody-based product characterization
2016
Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine
2004 Standout
Monitoring of Ligand-independent Dimerization and Ligand-induced Conformational Changes of Melatonin Receptors in Living Cells by Bioluminescence Resonance Energy Transfer
2002
Diet–microbiota interactions as moderators of human metabolism
2016 StandoutNature
Approval of the first biosimilar antibodies in Europe
2013
Practical method development for the separation of monoclonal antibodies and antibody-drug-conjugate species in hydrophobic interaction chromatoraphy, part 2: Optimization of the phase system
2016
Crystal structure of the β2 adrenergic receptor–Gs protein complex
2011 StandoutNatureNobel
The structure and function of G-protein-coupled receptors
2009 StandoutNatureNobel
Practical method development for the separation of monoclonal antibodies and antibody-drug-conjugate species in hydrophobic interaction chromatography, part 1: optimization of the mobile phase
2015
GPCR–Gα fusion proteins: molecular analysis of receptor–G-protein coupling
1999 StandoutNobel
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Migraine — Current Understanding and Treatment
2002 Standout
Structure of a nanobody-stabilized active state of the β2 adrenoceptor
2011 StandoutNatureNobel
Bacterial colonization factors control specificity and stability of the gut microbiota
2013 Nature
Characterization of cetuximab Fc/2 dimers by off-line CZE-MS
2016
An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior
2005 StandoutNobel
The role of insulin receptors and IGF-I receptors in cancer and other diseases
2008
Introduction to current and future protein therapeutics: A protein engineering perspective
2011
A review of central 5-HT receptors and their function
1999 Standout
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Crystal structure of the µ-opioid receptor bound to a morphinan antagonist
2012 StandoutNatureNobel
Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment
2016
Emerging formats for next-generation antibody drug conjugates
2015
Homo- and Hetero-oligomerization of Thyrotropin-releasing Hormone (TRH) Receptor Subtypes
2002 StandoutNobel
Structure of a β1-adrenergic G-protein-coupled receptor
2008 StandoutNatureNobel
Pharmacological significance of glycosylation in therapeutic proteins
2009
Sequential Binding of Agonists to the β2 Adrenoceptor
2003 StandoutNobel
A Yeast Genetic Screen Reveals a Critical Role for the Pore Helix Domain in TRP Channel Gating
2008 StandoutNobel
Roles of the metallothionein family of proteins in the central nervous system
2001
Programmable design of orthogonal protein heterodimers
2018 StandoutNatureNobel
Computational design of ligand-binding proteins with high affinity and selectivity
2013 StandoutNatureNobel
Antibody-drug conjugates
2013
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Agonist-specific Transactivation of Phosphoinositide 3-Kinase Signaling Pathway Mediated by the Dopamine D2 Receptor
2003
Structural basis of receptor recognition by SARS-CoV-2
2020 StandoutNature
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Characterization of Therapeutic Antibodies and Related Products
2012
Donitriptan, a Unique High‐Efficacy 5‐HT1B/1DAgonist: Key Features and Acute Antimigraine Potential
2000
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Roles of G‐protein‐coupled receptor dimerization
2004
Distinct conformational changes in β-arrestin report biased agonism at seven-transmembrane receptors
2008 StandoutNobel
Cholesterol increases kinetic, energetic, and mechanical stability of the human β2-adrenergic receptor
2012 StandoutNobel
G Protein–Coupled Receptor Oligomerization
2004
The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.
2013
Marine Indole Alkaloids: Potential New Drug Leads for the Control of Depression and Anxiety
2010 Standout
MOD-1 is a serotonin-gated chloride channel that modulates locomotory behaviour in C. elegans
2000 StandoutNatureNobel
The Type 1 Insulin-Like Growth Factor Receptor Pathway
2008
Time Resolved Native Ion-Mobility Mass Spectrometry to Monitor Dynamics of IgG4 Fab Arm Exchange and “Bispecific” Monoclonal Antibody Formation
2013
Myocyte Adrenoceptor Signaling Pathways
2003 StandoutScienceNobel
The second extracellular loop of the dopamine D2receptor lines the binding-site crevice
2004
Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine‐linked antibody drug conjugate
2015
Cutting‐edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies
2015
A Pictet-Spengler ligation for protein chemical modification
2012 StandoutNobel
Functional reconstitution of β2-adrenergic receptors utilizing self-assembling Nanodisc technology
2006
A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer
2002
Marketing approval of mogamulizumab
2012
Monobodies and other synthetic binding proteins for expanding protein science
2017
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
MERS-CoV spike protein: a key target for antivirals
2016
Serotonin Receptors
2008
Characterization of therapeutic antibodies and related products by two-dimensional liquid chromatography coupled with UV absorbance and mass spectrometric detection
2016
Alpha1-adrenergic receptors: new insights and directions.
2001
Tandem Native Mass-Spectrometry on Antibody–Drug Conjugates and Submillion Da Antibody–Antigen Protein Assemblies on an Orbitrap EMR Equipped with a High-Mass Quadrupole Mass Selector
2015
Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion
2013
Exploration of Fluorine Chemistry at the Multidisciplinary Interface of Chemistry and Biology
2013
Protein Glycoengineering Enabled by the Versatile Synthesis of Aminooxy Glycans and the Genetically Encoded Aldehyde Tag
2011 StandoutNobel
The Binding Site of Aminergic G Protein–Coupled Receptors: The Transmembrane Segments and Second Extracellular Loop
2002
Functional Role of a Conserved Motif in TM6 of the Rat μ Opioid Receptor: Constitutively Active and Inactive Receptors Result from Substitutions of Thr6.34(279) with Lys and Asp
2001
Innovative Native MS Methodologies for Antibody Drug Conjugate Characterization: High Resolution Native MS and IM-MS for Average DAR and DAR Distribution Assessment
2014
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Metals in Neurobiology: Probing Their Chemistry and Biology with Molecular Imaging
2008 Standout
Transduction of Receptor Signals by ß-Arrestins
2005 StandoutScienceNobel
Works of Thierry Wurch being referenced
F 11356, a Novel 5-Hydroxytryptamine (5-HT) Derivative with Potent, Selective, and Unique High Intrinsic Activity at 5-HT1B/1D Receptors in Models Relevant to Migraine
1999
Pharmacology of cloned human 5-HT1D receptor-mediated functional responses in stably transfected rat C6-glial cell lines: further evidence differentiating human 5-HT1D and 5-HT1B receptors
1996
Recombinant saphenous vein 5‐HT1Breceptors of the rabbit: comparative pharmacology with human 5‐HT1Breceptors
1997
Functional responses and in vivo anti-tumour activity of h7C10: A humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors
2007
Pharmacological analysis of G‐protein activation mediated by guinea‐pig recombinant 5‐HT1B receptors in C6‐glial cells: similarities with the human 5‐HT1B receptor
1998
Review: Amino acid domains involved in constitutive activation of G-protein-coupled receptors
1998
Expression of human metallothionein-III confers protection against serumfree exposure of stably transfected Chinese hamster ovary CHO-K1 cells
1995
Chimeric Receptor Analysis of the Ketanserin Binding Site in the Human 5-Hydroxytryptamine1D Receptor: Importance of the Second Extracellular Loop and Fifth Transmembrane Domain in Antagonist Binding
1998
GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins
2009
Evidence for protean agonism of RX 831003 at α2A-adrenoceptors by co-expression with different Gα protein subunits
2002
Agonist‐independent and ‐dependent oligomerization of dopamine D2 receptors by fusion to fluorescent proteins
2001
9th Annual European Antibody Congress, November 11–13, 2013, Geneva, Switzerland
2014
8thAnnual European Antibody Congress 2012
2013
Peptides as tools and drugs for immunotherapies
2007
5th European Antibody Congress 2009
2010
Coupling of Canine Serotonin 5‐HT1B and 5‐HT1D Receptor Subtypes to the Formation of Inositol Phosphates by Dual Interactions with Endogenous Gi/o and Recombinant Gα15 Proteins
2000
Modulation of 5-HT1A receptor signalling by point-mutation of cysteine351 in the rat Gαo protein
1999
Development of Novel Protein Scaffolds as Alternatives to Whole Antibodies for Imaging and Therapy: Status on Discovery Research and Clinical Validation
2008
Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept
2012
Trends in Glycosylation, Glycoanalysis and Glycoengineering of Therapeutic Antibodies and Fc-Fusion Proteins
2008
Pharmacological analysis of a dopamine D2Short:Gαofusion protein expressed in Sf9 cells
2003
Strategies and challenges for the next generation of therapeutic antibodies
2010
6thAnnual European Antibody Congress 2010
2011
How Efficacious are 5-HT 1B/D Receptor Ligands: an Answer from GTPγS Binding Studies with Stably Transfected C6-glial Cell Lines
1997
The next generation of antibody-drug conjugates comes of age.
2010
A modified overlap extension PCR method to create chimeric genes in the absence of restriction enzymes
1998
New Substituted 1-(2,3-Dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl Derivatives with α2-Adrenoceptor Antagonist Activity
2000
Activation of constitutive 5-hydroxytryptamine1B receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its Goα protein interactions
1999